[Itraconazole in systemic fungal infections. Clinical profile and future trends].
Fernández Fernández
A
A
Departamento Médico Janssen-Cilag, Madrid.
Esteban Montero
S
S
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000188:drug therapy; D004935:Esophageal Diseases / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D016919:Meningitis, Cryptococcal / Q000188:drug therapy; D009181:Mycoses / Q000188:drug therapy*; D010608:Pharyngeal Diseases / Q000188:drug therapy; D014330:Tropical Medicine
D000935:Antifungal Agents; D017964:Itraconazole; D000666:Amphotericin B